Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 11Terminated 8Withdrawn 7Recruiting 6Active not recruiting 5Unknown 2Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Lymphoid 1

Conditions

Lymphoma, Follicular 1Advanced Solid Tumors 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × duvelisib × Clear all
NCT05508659 2022-08-19

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1/2 Unknown
128 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04707079 2021-01-13

A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Unknown
24 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡